Lumos Pharma, Inc.
Index- P/E- EPS (ttm)-3.40 Insider Own9.70% Shs Outstand8.39M Perf Week-5.16%
Market Cap41.87M Forward P/E- EPS next Y-3.75 Insider Trans1.18% Shs Float5.57M Perf Month-42.78%
Income-28.50M PEG- EPS next Q-0.96 Inst Own30.80% Short Float / Ratio3.24% / 9.38 Perf Quarter-38.69%
Sales1.20M P/S34.89 EPS this Y-291.90% Inst Trans7.75% Short Interest0.18M Perf Half Y-31.33%
Book/sh8.07 P/B0.64 EPS next Y-1.60% ROA-31.80% Target Price22.00 Perf Year-30.03%
Cash/sh9.07 P/C0.57 EPS next 5Y15.20% ROE-36.40% 52W Range4.47 - 10.27 Perf YTD-25.69%
Dividend- P/FCF- EPS past 5Y32.70% ROI-34.50% 52W High-49.85% Beta1.04
Dividend %- Quick Ratio14.40 Sales past 5Y-63.60% Gross Margin- 52W Low15.34% ATR0.37
Employees32 Current Ratio14.40 Sales Q/Q- Oper. Margin- RSI (14)27.33 Volatility5.53% 8.59%
OptionableNo Debt/Eq0.00 EPS Q/Q3.50% Profit Margin- Rel Volume0.87 Prev Close5.10
ShortableYes LT Debt/Eq0.00 EarningsNov 14 BMO Payout- Avg Volume19.22K Price5.15
Recom2.00 SMA20-19.98% SMA50-35.55% SMA200-37.95% Volume16,636 Change1.07%
Mar-11-21Upgrade Stifel Hold → Buy $4 → $24
Dec-03-20Initiated Cantor Fitzgerald Buy $32
Aug-26-20Initiated Piper Sandler Overweight $26
Aug-17-20Resumed ROTH Capital Buy $51
Aug-04-20Initiated H.C. Wainwright Buy $33
Nov-29-22 04:05PM
Nov-22-22 04:05PM
Nov-14-22 06:10AM
Sep-26-22 04:05PM
09:00AM Loading…
Aug-31-22 09:00AM
Aug-16-22 07:30AM
Aug-09-22 04:01PM
Jul-27-22 04:05PM
Jul-24-22 08:27AM
Jul-20-22 08:32PM
May-16-22 04:05PM
May-10-22 04:01PM
May-06-22 10:25AM
May-05-22 09:00AM
09:00AM Loading…
Apr-26-22 09:00AM
Apr-11-22 08:30AM
Mar-23-22 04:05PM
Mar-10-22 04:01PM
Feb-23-22 09:00AM
Feb-14-22 12:05PM
Jan-05-22 09:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-08-21 09:38AM
Nov-24-21 10:00AM
Nov-15-21 11:14AM
Nov-10-21 05:06PM
10:42AM Loading…
Nov-08-21 10:42AM
Nov-03-21 04:01PM
Oct-21-21 04:05PM
Sep-02-21 08:00AM
Aug-16-21 09:58AM
Aug-05-21 08:00AM
Aug-03-21 08:00AM
Aug-02-21 08:00AM
Jul-26-21 04:18PM
Jul-22-21 08:00AM
Jul-20-21 04:01PM
Jun-28-21 08:00AM
May-19-21 09:00AM
May-13-21 09:00AM
May-05-21 04:01PM
Apr-28-21 09:00AM
Apr-27-21 08:00AM
Apr-20-21 04:05PM
Apr-14-21 04:05PM
Mar-20-21 11:00AM
Mar-11-21 04:05PM
Mar-09-21 04:05PM
Mar-04-21 09:00AM
Mar-02-21 04:05PM
Feb-22-21 04:15PM
Feb-16-21 04:01PM
Dec-18-20 09:00AM
Dec-16-20 02:19AM
Nov-30-20 05:35PM
Nov-23-20 07:43PM
Nov-10-20 04:01PM
Nov-03-20 12:30PM
Oct-29-20 09:00AM
Oct-27-20 04:01PM
Aug-27-20 09:00AM
Aug-13-20 04:01PM
Jul-28-20 04:01PM
Jul-27-20 04:05PM
Jun-19-20 08:21AM
Jun-10-20 03:41PM
May-28-20 04:01PM
May-27-20 04:27PM
May-26-20 10:36AM
Apr-24-20 08:00AM
Apr-02-20 04:05PM
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCracken Joseph SDirectorNov 16Buy5.034,00020,12015,721Nov 18 04:31 PM
Hawkins Richard JChief Executive OfficerSep 23Buy8.802081,8304,469Sep 23 05:05 PM
Hawkins Richard JChief Executive OfficerSep 21Buy8.842,21419,5724,261Sep 23 05:05 PM
Hawkins Richard JChief Executive OfficerSep 20Buy8.751,50613,1782,047Sep 21 06:45 PM
Hawkins Richard JChief Executive OfficerSep 19Buy8.655414,680541Sep 21 06:45 PM
Raffin Thomas A.DirectorAug 25Buy8.461,1509,7299,406Aug 26 05:00 PM
McCracken Joseph SDirectorAug 25Buy8.603,17027,26211,721Aug 26 04:59 PM
McKew John C.Chief Scientific OfficerAug 02Sale8.113,40727,63124,602Aug 03 11:25 AM
McKew John C.Chief Scientific OfficerJun 06Sale7.621691,28829,102Jun 07 04:23 PM
McKew John C.Chief Scientific OfficerApr 05Sale8.322,21418,42029,271Apr 05 05:29 PM